HBV genotypes: Relevance to natural history, pathogenesis and treatment of chronic hepatitis B

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1169-1186

  Kim, Beom Kyung ^a   Revill, Peter A ^b   Ahn, Sang Hoon ^a,c,d  

^a Yonsei University College of Medicine   (South Korea)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c Yonsei University   (South Korea)

^d Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

DISEASE COURSE; DRUG RESPONSE; ENDEMIC DISEASE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS CLASSIFICATION; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

AFRICA; ANTIVIRAL AGENTS; ASIA; CARCINOMA, HEPATOCELLULAR; CONTINENTAL POPULATION GROUPS; EUROPE; GENES, VIRAL; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; MUTATION RATE; NORTH AMERICA; PHYLOGEOGRAPHY; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 83455179343     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1982     Document Type: Review

References (171)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538. (Pubitemid 44307383)
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107. (Pubitemid 38365759)
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
5. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402-409. (Pubitemid 46765200)
6. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010; 53:20-28.
7. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8 Suppl:S18-20. (Pubitemid 20154750)
8. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990; 263:1218-1222. (Pubitemid 20069919)
9. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14 Suppl 1:6-10.
10. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009; 3:334-342.
11. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. E antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294:746-749.
12. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099-1102. (Pubitemid 14242389)
13. Li XM, Shi MF, Yang YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004; 10:3215-3217.
14. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170:1418-1423. (Pubitemid 24369900)
15. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009; 150:33-39.
16. Hadziyannis S. Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries. J Hepatol 2011; 55:183-191.
17. Whittle H, Inskip H, Bradley AK, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990; 161:1112-1115. (Pubitemid 20177869)
18. Allain JP, Candotti D, Soldan K, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003; 101:2419-2425. (Pubitemid 36302091)
19. Roingeard P, Diouf A, Sankale JL, et al. Perinatal transmission of hepatitis B virus in Senegal, west Africa. Viral Immunol 1993; 6:65-73. (Pubitemid 23108509)
20. Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 1998; 147:478-487. (Pubitemid 28146108)
21. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146:198-204. (Pubitemid 12009784)
22. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599-603. (Pubitemid 15102154)
23. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17:1730-1733. (Pubitemid 29138908)
24. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 Suppl 1:S64-S69. (Pubitemid 37222649)
25. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133:1452-1457. (Pubitemid 350029740)
26. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis - United States, 2006. MMWR Surveill Summ 2008; 57:1-24.
27. Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157:467-471. (Pubitemid 36258602)
28. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007; 13:14-21. (Pubitemid 46165459)
29. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198:489-503.
30. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74. (Pubitemid 30047907)
31. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011; 26 Suppl 1:123-130.
32. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17:643-650.
33. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005; 12:456-464. (Pubitemid 41224248)
34. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. J Med Virol 2005; 75:513-521. (Pubitemid 40293518)
35. Kramvis A, Restorp K, Norder H, Botha JF, Magnius LO, Kew MC. Full genome analysis of hepatitis B virus genotype E strains from South-Western Africa and Madagascar reveals low genetic variability. J Med Virol 2005; 77:47-52. (Pubitemid 41076475)
36. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. J Med Virol 2005; 75:513-521. (Pubitemid 40293518)
37. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 2007; 37:S9-S19. (Pubitemid 47086511)
38. Tanaka Y, Hasegawa I, Kato T, et al. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 2004; 40:747-755. (Pubitemid 39265598)
39. Revill PA, Littlejohn M, Ayres A, et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS 2007; 21:1701-1710. (Pubitemid 47237556)
40. Kurbanov F, Tanaka Y, Fujiwara K, et al. A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 2005; 86:2047-2056. (Pubitemid 40916389)
41. Sakamoto T, Tanaka Y, Simonetti J, et al. Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. J Infect Dis 2007; 196:1487-1492. (Pubitemid 351411985)
42. Kobayashi M, Suzuki F, Akuta N, et al. Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B. J Gastroenterol Hepatol 2005; 20:570-576. (Pubitemid 40755269)
43. Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124:925-932. (Pubitemid 36389795)
44. Sugauchi F, Orito E, Ichida T, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124:925-932. (Pubitemid 36389795)
45. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44:326-334. (Pubitemid 44214871)
46. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43:411-417.
47. Chan HL, Tsui SK, Tse CH, et al. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis 2005; 191:2022-2032. (Pubitemid 40800572)
48. Huy TT, Ushijima H, Quang VX, et al. Genotype C of hepatitis B virus can be classified into at least two subgroups. J Gen Virol 2004; 85:283-292. (Pubitemid 38262563)
49. Ahn SH, Yuen L, Revill P. Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology 2009; 52:321-322.
50. Sakamoto T, Tanaka Y, Orito E, et al. Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol 2006; 87:1873-1882. (Pubitemid 43985870)
51. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-182.
52. Ahn SH, Yuen L, Han KH, et al. Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol 2010; 82:1126-1134.
53. Chan HL, Wong GL, Tse CH, et al. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol 2009; 7:1361-1366.
54. Zhu L, Tse CH, Wong VW, Chim AM, Leung KS, Chan HL. A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. J Viral Hepat 2008; 15:449-458. (Pubitemid 351677552)
55. Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125:107-116. (Pubitemid 36799112)
56. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33:430-439. (Pubitemid 30663381)
57. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9:25-39. (Pubitemid 46730281)
58. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005; 77:173-179. (Pubitemid 41285783)
59. Echevarriá JM, Leon P. Hepatitis B virus genotypes identified by a Line Probe Assay (LiPA) among chronic carriers from Spain. Enferm Infecc Microbiol Clin 2004; 22:452-454. (Pubitemid 39506092)
60. Suzuki S, Sugauchi F, Orito E, et al. Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d'Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E. J Med Virol 2003; 69:459-465. (Pubitemid 36249857)
61. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14:1-21.
62. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83:2059-2073. (Pubitemid 34846468)
63. Kato H, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 2002; 35:922-929. (Pubitemid 34258388)
64. Devesa M, Pujol FH. Hepatitis B virus genetic diversity in Latin America. Virus Res 2007; 127:177-184. (Pubitemid 47064410)
65. Huy TTT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol 2008; 82:5657-5663. (Pubitemid 351705274)
66. Hannoun C, Norder H, Lindh M. An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam. J Gen Virol 2000; 81:2267-2272.
67. Kurbanov F, Tanaka Y, Kramvis A, Simmonds P, Mizokami M. When should "I" consider a new hepatitis B virus genotype? J Virol 2008; 82:8241-8242.
68. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009; 83:10538-10547.
69. EASL. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38:533-540.
70. Chang MH, Hwang LY, Hsu HC, Lee CY, Beasley RP. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology 1988; 8:374-377.
71. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984; 13:385-391. (Pubitemid 14102325)
72. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87:6599-6603.
73. Hsu HY, Chang MH, Hsieh KH, et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15:770-776.
74. Chu CM, Hung S, Lin J, Tai D, Liaw Y. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116:829-834. (Pubitemid 38721324)
75. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49:S45-S55.
76. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45:102-110. (Pubitemid 46150869)
77. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway. J Hepatol 2011; 55:762-769.
78. Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105:1141-1151. (Pubitemid 23281504)
79. Hsu HC, Su IJ, Lai MY, et al. Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol 1987; 5:45-50.
80. Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 2004; 144:397-399.
81. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995; 22:1387-1392.
82. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756-1762. (Pubitemid 34651418)
83. Yuen MF, Sablon E, Yuan H, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37:562-567. (Pubitemid 36258778)
84. Song E, Dusheiko GM, Bowyer S, Kew MC. Hepatitis B virus replication in southern Africa blacks with HBsAg-positive hepatocellular carcinoma. Hepatology 1984; 4:608-610. (Pubitemid 14051124)
85. Botha JF, Ritchie MJ, Dusheiko GM, Mouton HW, Kew MC. Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet 1984; 1:1210-1212. (Pubitemid 14105856)
86. Ahn SH, Kramvis A, Kawai S, et al. Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology 2003; 125:1370-1378. (Pubitemid 37409757)
87. Yuen MF, Lai CL. Hepatitis B virus genotypes: natural history and implications for treatment. Expert Rev Gastroenterol Hepatol 2007; 1:321-328.
88. McMillan JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996; 24:1371-1378. (Pubitemid 26399033)
89. Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22:1641-1647.
90. Alward WL, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151:604-609. (Pubitemid 15102155)
91. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13:627-631.
92. Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135:1192-1199.
93. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9:52-61. (Pubitemid 36002487)
94. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
95. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34:306-313. (Pubitemid 32176454)
96. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624. (Pubitemid 32927983)
97. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. (Pubitemid 350047463)
98. Arauz-Ruiz P, Norder H, Visona KA, Magnius LO. Genotype F prevails in HBV infected patients of Hispanic origin in Central America and may carry the precore stop mutant. J Med Virol 1997; 51:305-312. (Pubitemid 27148580)
99. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J Infect Dis 1997; 175:1285-1293 (Pubitemid 27225029)
100. Dimou E, Rapti I, Kostamena A, Laras A, Hadziyannis S. Development of precore and basic core promoter HBV mutations in chronic hepatitis B genotypes D and A. A prospecitve study in a Caucasian population. Hepatology 2009; 50 Suppl 4:983A.
101. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42:188-194. (Pubitemid 40143464)
102. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-768. (Pubitemid 33051260)
103. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45:1187-1192.
104. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856. (Pubitemid 35408309)
105. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010; 15 Suppl 3:25-33.
106. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51:1531-1537.
107. Bahn A, Gerner P, Martin U, Bortolotti F, Wirth S. Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol 1997; 27:973-978. (Pubitemid 27523954)
108. Komori M, Yuki N, Nagaoka T, et al. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J Hepatol 2001; 35:798-804. (Pubitemid 34717672)
109. Loriot MA, Marcellin P, Walker F, et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997; 27:251-258. (Pubitemid 27366203)
110. Raimondo G, Navarra G, Mondello S, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48:743-746.
111. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34:194-203. (Pubitemid 32591500)
112. Minuk GY, Sun D, Uhanova J, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005; 42:480-485. (Pubitemid 40342925)
113. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077-4081. (Pubitemid 24139576)
114. Choi JW, Ahn SH, Park JY, et al. Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. J Med Virol 2009; 81:594-601.
115. Kim JK, Chang HY, Lee JM, et al. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol 2009; 81:1002-1008.
116. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26 Suppl 1:144-152
117. Lin CL, Liu CH, Chen W, et al. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22:1098-1103. (Pubitemid 47019845)
118. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26 Suppl 1:123-130.
119. Liu Y, Zhong Y, Zou Z, et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol 2010 47:243-247.
120. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130:1153-1168.
121. Rodriguez-Frias F, Jardi R, Buti M, et al. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection. J Viral Hepat 2006; 13:343-350.
122. Hsu YS, Chien R, Yeh C, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527. (Pubitemid 34966908)
123. Manno M, Camm C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127:756-763. (Pubitemid 39208409)
124. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145:1039-1047.
125. Iloeje UH, Yang HI, Su J, Jen C, You S, Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
126. Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94:2246-2250. (Pubitemid 29374561)
127. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493-496.
128. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45-52.
129. Jang JW, Lee YC, Kim MS, et al. A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. J Viral Hepat 2007; 14:169-175.
130. Moreno-Otero R, Garca-Monzn C, Garca-Snchez A, Buey LG, Pajares JM, Di Bisceglie AM. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol 1991; 86:560-564.
131. Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8:1651-1654. (Pubitemid 19021903)
132. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10:198-202. (Pubitemid 19190211)
133. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801. (Pubitemid 23174709)
134. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129-1133.
135. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432-438.
136. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106:1000-1005.
137. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
138. Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology 2005; 48:23-28. (Pubitemid 40529207)
139. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134-1143.
140. Prates MD, Torres FO. A cancer survey in Lourenço Marques, Portuguese East Africa. J Natl Cancer Inst 1965; 35:729-757.
141. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-680.
142. Kirk GD, Lesi OA, Mendy M, et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004; 39:211-219. (Pubitemid 38461484)
143. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987; 7:302-306. (Pubitemid 17062720)
144. Nguyen VTT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009; 16:453-463.
145. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118:191-194. (Pubitemid 23034804)
146. Benvegnú L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83:901-909. (Pubitemid 28401923)
147. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-2895. (Pubitemid 35265444)
148. Chen YC, Chu C, Yeh C, Liaw Y. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007; 1:267-273.
149. Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78:459-465. (Pubitemid 43346896)
150. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9:235-241.
151. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
152. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gambia: 1988-97. Br J Cancer 2001; 84:1207-1214. (Pubitemid 32511338)
153. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008; 13:211-220. (Pubitemid 351535372)
154. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine,
155. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013. (Pubitemid 40873918)
156. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. (Pubitemid 40091801)
157. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357-1364. (Pubitemid 40770289)
158. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44:541-548. (Pubitemid 46233256)
159. Liu CJ, Lai MY, Chao YC, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43:742-749.
160. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48:8-16. (Pubitemid 26143037)
161. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705. (Pubitemid 46662938)
162. Flink HJ, Hansen BE, Heathcote EJ, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 2006; 101:2523-2529. (Pubitemid 44665248)
163. Hadziyannis S, Lau GK, Marcellin P, Piratvisuth T, Cooksley G, Borino F. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alpha-2a (40KD) (Pegasys). J Hepatol 2005; 42 Suppl 2:178.
164. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008; 13:613-624.
165. Damerow H, Yuen L, Wiegand J, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010; 82:1850-1858.
166. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172*mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88-98. (Pubitemid 351975534)
167. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther 2008; 13:875-879.
168. Yuen L, Ayres A, Littlejohn M, Edwards R, Locarnini S. Evolution of the Hepatitis B surface antigen in European and Asian HBV genotypes during the era of antiviral therapy. Hepatol Int 2011; 5:150A.
169. Munoz A, Chen JG, Egner PA, et al. Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis 2011; 32:860-865.
170. Kuang SY, Jackson PE, Wang JB, et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 2004; 101:3575-3580. (Pubitemid 38338237)
171. US Centers for Disease Control and Prevention. CDC Travel's Health - 2012 Yellow Book. Chapter 3 - Hepatitis B. (Updated 1 July 2011. Accessed 8 November 2011) Available from http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3- infectious-diseases-related-to-travel/hepatitis-b.htm